A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
Riely GJ, Johnson ML, Medina C, Rizvi NA, Miller VA, Kris MG, Pietanza MC, Azzoli CG, Krug LM, Pao W, Ginsberg MS.
Riely GJ, et al. Among authors: johnson ml.
J Thorac Oncol. 2011 Aug;6(8):1435-7. doi: 10.1097/JTO.0b013e318223c099.
J Thorac Oncol. 2011.
PMID: 21847063
Free article.
Clinical Trial.